Intelligent Investor

Universal Biosensors, Inc. (ASX: UBI) - Announcements

- Current share price for UBI : $0.135

ASX company news and announcements for Universal Biosensors, Inc. (UBI) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Universal Biosensors, Inc. (UBI) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Universal Biosensors, Inc. (UBI), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Universal Biosensors, Inc. (UBI)

Market Cap ($m) Headline Announcement date/time + Price at ann'ment + Current price + Price
7D Avg
Gain/Loss
$40 Notice of Meeting/Proxy Statement 11 Apr 2023 8:15AM $0.280 $0.135 $0.130 fallen by 51.79%
$40 UBI submits Xprecia Prime 510K Application to FDA 24 Mar 2023 10:45AM $0.245 $0.135 $0.130 fallen by 44.90%
$40 Appendix 3Y - Graham McLean 16 Mar 2023 8:40AM $0.245 $0.135 $0.130 fallen by 44.90%
$40 FY2022 Corporate Governance Statement & Appendix 4G 14 Mar 2023 11:43AM $0.250 $0.135 $0.130 fallen by 46%
$40 FY2022 Corporate Governance Statement and Appendix 4G 24 Feb 2023 4:08PM $0.280 $0.135 $0.130 fallen by 51.79%
$40 UBI Investor Presentation FY2022 24 Feb 2023 4:08PM $0.280 $0.135 $0.130 fallen by 51.79%
$40 Appendix 4E and Annual Report on Form 10-K FY2022 24 Feb 2023 3:53PM $0.280 $0.135 $0.130 fallen by 51.79%
$40 UBI launch another new Sentia Test 21 Feb 2023 8:32AM $0.315 $0.135 $0.130 fallen by 57.14%
$40 Change in substantial holding 8 Feb 2023 9:59AM $0.330 $0.135 $0.130 fallen by 59.09%
$40 UBI makes first sales of Xprecia Prime in Europe 6 Feb 2023 8:58AM $0.305 $0.135 $0.130 fallen by 55.74%
$40 UBI launches new product - Fructose Test for Sentia 30 Jan 2023 8:37AM $0.320 $0.135 $0.130 fallen by 57.81%
$40 December 2022 Quarterly Activity Report and Appendix 4C 27 Jan 2023 4:13PM $0.320 $0.135 $0.130 fallen by 57.81%
$40 UBI completes Xprecia Prime clinical trial in USA 23 Jan 2023 10:21AM $0.260 $0.135 $0.130 fallen by 48.08%
$40 UBI appoints a new Chairman 16 Jan 2023 9:10AM $0.270 $0.135 $0.130 fallen by 50%
$40 Application for quotation of securities - UBI 3 Jan 2023 2:10PM $0.225 $0.135 $0.130 fallen by 40%
$40 Notification of cessation of securities - UBI 13 Dec 2022 4:05PM $0.230 $0.135 $0.130 fallen by 41.30%
$40 Appendix 3Y - Graham McLean 13 Dec 2022 4:03PM $0.230 $0.135 $0.130 fallen by 41.30%
$40 UBI receives $3.9M under the R&D Tax Incentive Rebate 21 Nov 2022 12:50PM $0.240 $0.135 $0.130 fallen by 43.75%
$40 UBI's Cancer Biomarker work gets published by ACS Sensors 17 Nov 2022 9:22AM $0.235 $0.135 $0.130 fallen by 42.55%
$40 Appendix 3Y - Craig Coleman 17 Nov 2022 9:20AM $0.235 $0.135 $0.130 fallen by 42.55%
$40 UBI Investor Presentation 9 Nov 2022 8:35AM $0.260 $0.135 $0.130 fallen by 48.08%
$40 Change of Registry Address 31 Oct 2022 4:08PM $0.250 $0.135 $0.130 fallen by 46%
$40 Q3 2022 Results Presentation 27 Oct 2022 3:43PM $0.275 $0.135 $0.130 fallen by 50.91%
$40 September 2022 Quarterly Activity Report and Appendix 4C 27 Oct 2022 3:40PM $0.275 $0.135 $0.130 fallen by 50.91%
$40 Market Update 6 Sep 2022 10:09AM $0.250 $0.135 $0.130 fallen by 46%

76 - 100 of 579 results

Page 4 of 24

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.